Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus

Authors

  • Aline Vitali Grando Universidade do Sul de Santa Catarina; Faculdade de Medicina; Departamento de Ciências Biológicas e da Saúde e de Ciências Sociais Aplicadas
  • Paulo Roberto Abrão Ferreira Universidade Federal de São Paulo
  • Mário Guimarães Pessôa Universidade de São Paulo; Faculdade de Medicina; Divisão de Gastroenterologia e Hepatologia
  • Daniel Ferraz de Campos Mazo Universidade de São Paulo; Faculdade de Medicina; Divisão de Gastroenterologia e Hepatologia
  • Carlos Eduardo Brandão-Mello Universidade Federal do Estado do Rio de Janeiro; Departamento de Clinica Médica
  • Tânia Reuter Universidade Federal do Espírito Santo
  • Ana de Lourdes Candolo Martinelli Universidade de São Paulo; Faculdade de Medicina de Ribeirão Preto; Divisão de Gastroenterologia
  • Mário Peribanez Gonzalez Instituto de Infectologia Emilio Ribas
  • Ana Catharina Seixas-Santos Nastri Universidade de São Paulo; Faculdade de Medicina; Departamento de Doenças Infecciosas e Parasitárias
  • Aléia Faustina Campos Universidade de São Paulo; Faculdade de Medicina; Departamento de Doenças Infecciosas e Parasitárias
  • Max Igor Banks Ferreira Lopes Universidade de São Paulo; Faculdade de Medicina; Departamento de Doenças Infecciosas e Parasitárias
  • José David Urbaez Brito Secretaria Estadual de Saúde; Unidade Mista de Saúde
  • Maria Cássia Mendes-Corrêa Universidade de São Paulo; Instituto de Medicina Tropical de São Paulo; Laboratório de Virologia

Keywords:

Hepatitis C, Chronic hepatitis C, Coinfection HCV-HIV, Interferons, Ribavirin, HCV genotypes

Abstract

Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC patients, and to evaluate sustained virological response (SVR) indicators and early treatment interruption due to serious adverse events (SAE). This was a retrospective observational study of GEN3/CHC patients, co-infected or not by HIV and treated with Peg-IFN/RBV in nine Brazilian healthcare centers. The study sample included 184 GEN3/CHC patients; 70 (38%) were co-infected with HIV. The overall SVR rate was 57.1% (95% CI 50-64). Among co-infected and mono-infected patients, the SVR rate was 51.4% (36/70) and 60.5% (69/114), respectively (p=0.241). Thirty-four (18.5%) patients experienced SAE and interrupted treatment. SVR was negatively associated with the use of Peg-IFN alpha 2b (PR 0.75; 95% CI 0.58-0.99; p=0.045) and to early treatment interruption due to SAE (PR 0.36; 95% CI 0.20-0.68; p=0.001). Early treatment interruption due to SAE was associated with age (PR 1.06; 95% CI 1.02-1.10; p<0.001) and occurrence of liver cirrhosis (PR 2.06; 95% CI 1.11-3.83; p=0.022). In conclusion, Peg-IFN/RBV might represent an adequate treatment option, mainly in young patients without advanced liver disease or when the use of direct-action drugs is limited to specific patient groups.

Downloads

Download data is not yet available.

Downloads

Published

2017-01-01

Issue

Vol. 59 (2017)

Section

Original Articles

How to Cite

Grando, A. V., Ferreira, P. R. A., Pessôa, M. G., Mazo, D. F. de C., Brandão-Mello, C. E., Reuter, T., Martinelli, A. de L. C., Gonzalez, M. P., Nastri, A. C. S.-S., Campos, A. F., Lopes, M. I. B. F., Brito, J. D. U., & Mendes-Corrêa, M. C. (2017). Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus. Revista Do Instituto De Medicina Tropical De São Paulo, 59, e67. https://revistas.usp.br/rimtsp/article/view/140682